Sanofi SA has entered a new partnership with Viz.ai and Regeneron to enhance the management and care of patients with chronic obstructive pulmonary disease (COPD). The collaboration aims to deploy and evaluate an AI-powered care improvement solution for high-risk COPD patients. This multi-year partnership will leverage Viz.ai's AI-driven technology to screen and triage patients using electronic health record (EHR) data, with the goal of improving access to care and patient outcomes. The Viz COPD module will utilize natural language processing to align with clinical guidelines, identifying high-risk individuals for further follow-up. This initiative reflects a significant step towards addressing the unmet needs in COPD care, a disease often underprioritized compared to other noncommunicable diseases.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.